Showing 19,141 - 19,160 results of 36,983 for search '(( significant ((clinical decrease) OR (clinical disease)) ) OR ( significant decrease decrease ))', query time: 0.65s Refine Results
  1. 19141

    Table5_Deciphering the role of lipid metabolism-related genes in Alzheimer’s disease: a machine learning approach integrating Traditional Chinese Medicine.xlsx by KeShangJing Wu (19931535)

    Published 2024
    “…The role of carbohydrates, particularly apolipoprotein E (ApoE), is pivotal in AD pathogenesis due to its involvement in lipid and cholesterol metabolism, and its status as a genetic predisposition factor for the disease. Despite its significance, the mechanistic contributions of Lipid Metabolism-related Genes (LMGs) to AD remain inadequately elucidated. …”
  2. 19142

    Dataset. by Mahdieh Nazari-Robati (22394355)

    Published 2025
    “…Polypills are utilized to improve cardiovascular disease (CVD) risk factors. The present observational study was nested within the PolyIran-Liver randomized controlled trial, which primarily assessed clinical outcomes in NAFLD patients. …”
  3. 19143
  4. 19144

    Data Sheet 1_A new strategy improving TB diagnosis: stratified urine LAM test based on lymphocyte counts.docx by Hongzhi Li (271473)

    Published 2025
    “…Patients with lymphocyte counts <0.8 × 10<sup>9</sup>/L were significantly more likely to have a positive AIMLAM result (OR = 9.431, 95% CI: 2.659–33.447, P = 0.001). …”
  5. 19145

    Supplementary file 1_Toxicity profiles of cyclin-dependent kinase 4/6 inhibitors: safety analysis from clinical trials and the FDA adverse event reporting system.docx by Jin Zhou (90734)

    Published 2025
    “…</p>Results<p>Combination therapy with CDK4/6 inhibitors significantly increased the risk of grade 3–5 AEs. FAERS analysis revealed that most AEs occurred within the first month of treatment, with the lowest incidence between the second and sixth months, followed by a significant rise thereafter. …”
  6. 19146

    Evaluation of orphan maintained biological medicinal products in the European Union between 2018 to 2023: a regulatory perspective by Paolo Caferra (17742726)

    Published 2024
    “…</p> <p>Among the 50 biological OMP maintained orphan designations, 68.0% had to demonstrate SB over existing treatments, with 91.2% leveraging the clinically relevant advantage area, utilizing better clinical efficacy (83.9%) and efficacy in subpopulations (38.7%) subdomains. …”
  7. 19147

    Data Sheet 1_Primary care and specialist physicians’ prescribing preferences for concurrent probiotic-antibiotic therapy: a multinational clinical practice survey across 13 countri... by Stephan R. Vavricka (8994197)

    Published 2025
    “…<p>Antibiotic-induced intestinal microbiota disruption represents a significant clinical concern, yet physician practices regarding concurrent probiotic supplementation remain poorly characterized across international healthcare systems. …”
  8. 19148

    Table 1_Clinical characteristics and antibody response to Omicron variants among solid carcinoma patients in China on the 2022.12–2023.4 wave of the COVID-19 pandemic.docx by Rongrong Dai (785070)

    Published 2024
    “…Background<p>China experienced a surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants after adjusting its zero-coronavirus disease 2019 (COVID-19) policy. Although infections with Omicron variants are generally less severe than infections with previous SARS-CoV-2 variants, the clinical characteristics, persistent symptoms, and antibody responses in solid carcinoma patients (SCPs) with COVID-19 during the Omicron wave are unclear.…”
  9. 19149
  10. 19150
  11. 19151
  12. 19152

    Fig 8 - by Mehrbod Vakhshoori (16615578)

    Published 2024
    Subjects:
  13. 19153
  14. 19154
  15. 19155
  16. 19156
  17. 19157
  18. 19158
  19. 19159
  20. 19160